Seamless phase I/II design for novel anticancer agents with competing disease progression

DOI10.1002/SIM.9080zbMATH Open1546.62097MaRDI QIDQ6627954

Author name not available (Why is that?), Shing M. Lee, Bin Cheng

Publication date: 29 October 2024

Published in: Statistics in Medicine (Search for Journal in Brave)

zbMATH Keywords

survival datacompeting risksdose-findingdisease progressiononcology

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Title not available (Why is that?)
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• A nonidentifiability aspect of the problem of competing risks.
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• Simple benchmark for complex dose finding studies
• Direct Parametric Inference for the Cumulative Incidence Function
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
• Bayesian optimal interval designs for phase I clinical trials
• A utility-based Bayesian phase I--II design for immunotherapy trials with progression-free survival end point

Related Items (1)

Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression

This page was built for publication: Seamless phase I/II design for novel anticancer agents with competing disease progression

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6627954)